Prognostic impact of matrix metalloproteinase-9 in operable non-small cell lung cancer

International Journal of Cancer

Volumn 103, Issue 5, 2003, Pages 647-651

  Sienel, Wulf ^a,b   Hellers, Joe ^a   Morresi Hauf, Alicia ^b   Lichtinghagen, Ralf ^c   Mutschler, Wolf ^a   Jochum, Marianne ^a   Klein, Christoph ^d   Passlick, Bernward ^a,b   Pantel, Klaus ^e  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Asklepios Fachklin Munchen Gauting ^*  (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Carcinoma; Extracellular matrix; Follow up study; Gelatinase b; Lung neoplasms; Matrix metalloproteinases; Multivariate analysis; Non small cell lung; Prognosis; Regression analysis; Survival analysis; Survival rate; Therapy

Indexed keywords

GELATINASE B;

ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; LYMPH NODES; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE;

EID: 0037455842     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10841     Document Type: Article

References (24)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
2. Howe HL, Wingo PA, Thun MJ, Ries LA, Rosenberg HM, Feigal EG, Edwards BK. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 2001;93:824-42.
3. Janssen-Heijnen ML, Gatta G, Forman D, Capocaccia R, Coebergh JW. Variation in survival of patients with lung cancer in Europe, 1985-1989. EUROCARE Working Group. Eur J Cancer 1998;34: 2191-6.
4. el Torky M, el Zeky F, Hall JC. Significant changes in the distribution of histologic types of lung cancer. A review of 4928 cases. Cancer 1990;65:2361-7.
5. Martini N, Bains MS, Burt ME, Zakowski MF, McCormack P, Rusch VW, Ginsberg RJ. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995;109:120-9.
6. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710 -7.
7. Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999;43(Suppl):S42-51.
8. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999;274:21491-4.
9. Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2000;19: 6642-50.
10. Cox G, Jones JL, O'Byrne KJ. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res 2000;6:2349-55.
11. Shou Y, Hirano T, Gong Y, Kato Y, Yoshida K, Ohira T, Ikeda N, Konaka C, Ebihara Y, Zhao F, Kato H. Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer. Br J Cancer 2001;85:1706-12.
12. Lichtinghagen R, Helmbrecht T, Arndt B, Boker KH. Expression pattern of matrix metalloproteinases in human liver. Eur J Clin Chem Clin Biochem 1995;33:65-71.
13. Geisler S, Lichtinghagen R, Boker KH, Veh RW. Differential distribution of five members of the matrix metalloproteinase family and one inhibitor (TIMP-1) in human liver and skin. Cell Tissue Res 1997;289:173-83.
14. Thomas P, Khokha R, Shepherd FA, Feld R, Tsao MS. Differential expression of matrix metalloproteinases and their inhibitors in nonsmall cell lung cancer. J Pathol 2000;190:150-6
15. Lebeau A, Nerlich AG, Sauer U, Lichtinghagen R, Lohrs U. Tissue distribution of major matrix metalloproteinases and their transcripts in human breast carcinomas. Anticancer Res 1999;19:4257-64.
16. Bachmeier BE, Boukamp P, Lichtinghagen R, Fusenig NE, Fink E. Matrix metalloproteinases-2,-3,-7,-9 and-10, but not MMP-11, are differentially expressed in normal, benign tumorigenic and malignant human keratinocyte cell lines. Biol Chem 2000;381:497-507.
17. Iwata H, Yamamoto M, Nemori R, Mizutanj M, Iwase T, Miura S, Obata Y, Hara Y, Omoto Y, Toyama T, Yamashita H, Iwase H, et al. Localization of gelatinolytic activity can be detected in breast cancer tissues by film in situ zymography. Breast Cancer 2001;8:111-5.
18. Furuya M, Ishikura H, Nemori R, Shibata M, Fujimoto S, Yoshiki T. Clarification of the active gelatinolytic sites in human ovarian neoplasms using in situ zymography. Hum Pathol 2001;32:163-8.
19. Bayer Corp. Bayer halts clinical trials evaluating MMPI. Press release, 1999.
20. British Biotech Plc. Reports of clinical studies with matrix metalloproteinase inhibitors in cancer. Press release, 2000.
21. Pfizer Corp. Pfizer discontinues Phase III trials of prinomastat in advanced cancers but continues multiple Phase II trials. Press release, 2000.
22. Kruger A, Soeltl R, Sopov I, Kopitz C, Arlt M, Magdolen V, Harbeck N, Gansbacher B, Schmitt M. Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis. Cancer Res 2001;61:1272-5.
23. Brown PD. Ongoing trials with matrix metalloproteinase inhibitors. Expert Opin Investig Drugs 2000;9:2167-77.
24. Minna JD, Sekido Y, Fong KM, Gazdar AF. Cancer of the lung. In: De Vita VTJ, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 1997, 2000. 858-911.